Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 58.91B |
| Revenue (ttm) | 10.60B |
| Net Income (ttm) | 3.41B |
| Shares Out | n/a |
| EPS (ttm) | 30.94 |
| PE Ratio | 17.30 |
| Forward PE | 16.12 |
| Dividend | 2.68 (0.35%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 436 |
| Average Volume | 1,207 |
| Open | 746.62 |
| Previous Close | 745.62 |
| Day's Range | 739.01 - 768.92 |
| 52-Week Range | 477.01 - 812.89 |
| Beta | n/a |
| RSI | 63.79 |
| Earnings Date | Feb 3, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Regeneron: The Turnaround Is Gaining Steam
Alvotech, Teva Secures U.S. License Entry Date For Eylea Biosimilar AVT06
(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a poten...
Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.
Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive Strengths
Regeneron Pharmaceuticals Inc (REGN)'s Winning Formula: Financial Metrics and Competitive Strengths
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow
Look beyond the healthcare company's recent setbacks.
Regeneron Pharmaceuticals (REGN) Receives Updated Analyst Ratings from Morgan Stanley | REGN ...
Regeneron Pharmaceuticals (REGN) Receives Updated Analyst Ratings from Morgan Stanley | REGN Stock News
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Wells Fargo Raises Price Target for Regeneron (REGN) to $745 | REGN Stock News
Wells Fargo Raises Price Target for Regeneron (REGN) to $745 | REGN Stock News
How Is The Market Feeling About Regeneron Pharmaceuticals Inc?
Regeneron Pharmaceuticals Inc's (NYSE: REGN) short interest as a percent of float has risen 10.49% since its last report. According to exchange reported data, there are now 3.15 million shares sold s...
Regeneron Pharmaceuticals Inc Roundtable Lynozyfic Transcript
Regeneron Pharmaceuticals Inc Roundtable Lynozyfic Transcript
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
The Investment Committee debate the latest Calls of the Day.
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
The Investment Committee debate the latest Calls of the Day.
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow tr...
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma
Regeneron (REGN) Showcases Promising Trial Data for Lynozyfic in Multiple Myeloma
Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed multiple myeloma...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Regeneron's experimental therapy combo effective in untreated cancer patients
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first p...
Regeneron Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Regeneron Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticals (REGN) to $1,057 | REGN ...
Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticals (REGN) to $1,057 | REGN Stock News
Market Whales and Their Recent Bets on REGN Options
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ: REGN) revealed 12 unusual trades. Delving in...
REGN: BMO Capital Raises Price Target and Maintains Outperform Rating | REGN Stock News
REGN: BMO Capital Raises Price Target and Maintains Outperform Rating | REGN Stock News